Plus Therapeutics Presents Promising Data from Clinical Trials; “Significant Clinical Interest” in Field

Clinical-stage pharmaceutical company, Plus Therapeutics (Nasdaq:PSTV), has presented data from two clinical trials evaluating its targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL) at the 35th Annual Congress of the European Association of Nuclear Medicine.

The Company’s ReSPECT-GBM presentation was selected for inclusion in the opening Plenary Highlights Lecture, signaling significant clinical interest in the field.

 Highlights

  • 186RNL is being evaluated for the treatment of leptomeningeal metastases and recurrent glioblastoma;
  • Treatment was well tolerated without dose limiting toxicities and all patients showed a decrease in spinal fluid tumor cell counts;
  • Plus Therapeutics’ leptomeningeal metastases trial is supported by a $17.6 million grant by the Cancer Prevention & Research Institute of Texas;
  • The Company plans to initiate a National Institutes of Health (NIH)-funded Phase 2 study in recurrent glioma by the end of 2022.

Plus Therapeutics develops, manufactures, and commercializes complex and innovative treatments for cancer and other life-threatening diseases.

Share This Article

 

About the Author

Plus Therapeutics Presents Promising Data from Clinical Trials; “Significant Clinical Interest” in Field

Editor Prism MarketView